Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.

Angelika Martina StarzerAnna S BerghoffRainer HamacherErwin TomasichKatharina FeldmannTeresa HatziioannouStefan TraintWolfgang LammIris M Noebauer-HuhmannJulia FurtnerLeonhard MüllauerGabriele AmannSebastian BauerHans-Ulrich SchildhausMatthias PreusserGerwin HellerThomas Brodowicz

Published in: Journal for immunotherapy of cancer (2021)

Our data demonstrate that tumor DNA methylation profiles may serve as a predictive marker for response to anti-PD-1 ICI therapy in sarcoma.

Keyphrases

dna methylation
end stage renal disease
gene expression
genome wide
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
electronic health record
stem cells
combination therapy
deep learning